Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease

Journal of Renal Nutrition

Volumn 23, Issue 5, 2013, Pages

  Cigarrán, Secundino ^a   Pousa, Montserrat ^a   Castro, María Jesús ^a   González, Berta ^a   Martínez, Aurelia ^a   Barril, Guillermina ^b   Aguilera, Abelardo ^b   Coronel, Francisco ^c   Stenvinkel, Peter ^d   Carrero, Juan Jesús ^d  

^a HOSPITAL DA COSTA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TESTOSTERONE;

AGED; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; GLOMERULUS FILTRATION RATE; HAND STRENGTH; HUMAN; IMPEDANCE; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ELECTRIC IMPEDANCE; GLOMERULAR FILTRATION RATE; HAND STRENGTH; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PHENOTYPE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TESTOSTERONE;

EID: 84882894573     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2012.08.007     Document Type: Article

References (40)

1. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimburger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
2. Fouque D., Kalantar-Zadeh K., Kopple J., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73:391-398.
3. Carrero J.J., Chmielewski M., Axelsson J., et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr 2008, 27:557-564.
4. Foley R.N., Wang C., Ishani A., Collins A.J., Murray A.M. Kidney function and sarcopenia in the united states general population: NHANES III. Am J Nephrol 2007, 27:279-286.
5. Feroze U., Noori N., Kovesdy C.P., et al. Quality-of-life and mortality in hemodialysis patients: roles of race and nutritional status. Clin J Am Soc Nephrol 2011, 6:1100-1111.
6. Chang Y.T., Wu H.L., Guo H.R., et al. Handgrip strength is an independent predictor of renal outcomes in patients with chronic kidney diseases. Nephrol Dial Transplant 2011, 26:3588-3595.
7. Leal V.O., Mafra D., Fouque D., Anjos L.A. Use of handgrip strength in the assessment of the muscle function of chronic kidney disease patients on dialysis: a systematic review. Nephrol Dial Transplant 2011, 26:1354-1360.
8. Meuwese C.L., Carrero J.J., Stenvinkel P. Recent insights in inflammation-associated wasting in patients with chronic kidney disease. Contrib Nephrol 2011, 171:120-126.
9. Du J., Hu Z., Mitch W.E. Molecular mechanisms activating muscle protein degradation in chronic kidney disease and other catabolic conditions. Eur J Clin Invest 2005, 35:157-163.
10. Carrero J.J., Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant 2012, [published online ahead of print]. doi:10.1093/ndt/gfs383.
11. Herbst K.L., Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004, 7:271-277.
12. Iglesias P., Carrero J.J., Diez J.J. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol 2012, 25:31-42.
13. Carrero J.J., Kyriazis J., Sonmez A., et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with ckd. Clin J Am Soc Nephrol 2012, 7:207-215.
14. Yilmaz M.I., Sonmez A., Qureshi A.R., et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:1617-1625.
15. Carrero J.J., Qureshi A.R., Nakashima A., et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011, 26:184-190.
16. Carrero J.J., Barany P., Yilmaz M.I., et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant 2012, 27:709-715.
17. Karakitsos D., Patrianakos A.P., De Groot E., et al. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 2006, 26:536-543.
18. Carrero J.J., Qureshi A.R., Parini P., et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009, 20:613-620.
19. Piccoli A., Rossi B., Pillon L., Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int 1994, 46:534-539.
20. Kotler D.P., Burastero S., Wang J., Pierson R.N. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996, 64:489S-497S.
21. Tenover J.S., Matsumoto A.M., Plymate S.R., Bremner W.J. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab 1987, 65:1118-1126.
22. Baumgartner R.N., Waters D.L., Gallagher D., Morley J.E., Garry P.J. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999, 107:123-136.
23. Heimburger O., Qureshi A.R., Blaner W.S., Berglund L., Stenvinkel P. Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 2000, 36:1213-1225.
24. Honda H., Qureshi A.R., Axelsson J., et al. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 2007, 86:633-638.
25. van den Beld A.W., de Jong F.H., Grobbee D.E., Pols H.A., Lamberts S.W. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000, 85:3276-3282.
26. Allan C.A., Strauss B.J., Burger H.G., Forbes E.A., McLachlan R.I. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008, 93:139-146.
27. Auyeung T.W., Lee J.S., Kwok T., et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol 2011, 164:811-817.
28. Ward K.A., Pye S.R., Adams J.E., et al. Influence of age and sex steroids on bone density and geometry in middle-aged and elderly European men. Osteoporos Int 2011, 22:1513-1523.
29. Ishibe S., Peixoto A.J. Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice. Semin Dial 2004, 17:37-43.
30. Szulc P., Claustrat B., Marchand F., Delmas P.D. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab 2003, 88:5240-5247.
31. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26:833-876.
32. Gentile M.A., Nantermet P.V., Vogel R.L., et al. Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. J Mol Endocrinol 2010, 44:55-73.
33. Bhasin S., Storer T.W., Berman N., et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996, 335:1-7.
34. Johansen K.L., Mulligan K., Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999, 281:1275-1281.
35. Johansen K.L., Painter P.L., Sakkas G.K., Gordon P., Doyle J., Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006, 17:2307-2314.
36. Eiam-Ong S., Buranaosot S., Wathanavaha A., Pansin P. Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease. J Ren Nutr 2007, 17:173-178.
37. Carrero J.J. Gender differences in chronic kidney disease: underpinnings and therapeutic implications. Kidney Blood Press Res 2010, 33:383-392.
38. Stenvinkel P., Barany P., Chung S.H., Lindholm B., Heimburger O. A comparative analysis of nutritional parameters as predictors of outcome inmale and female esrd patients. Nephrol Dial Transplant 2002, 17:1266-1274.
39. Srinivas-Shankar U., Roberts S.A., Connolly M.J., et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
40. Travison T.G., Basaria S., Storer T.W., et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2011, 66:1090-1099.